News

Gain-of-function STAT4 variants in patients with disabling pansclerotic morphea suggest a potential therapeutic role for JAK inhibition, resulting in improved clinical symptoms and inflammatory markers.

An analysis of the Ontario Health WTIS database suggests the presence of systematic sex-based differences could be affecting the timeliness of ophthalmic surgery for women.

The results show engagement in the Telehealth Collaborative Care program visits was greater compared to the Telehealth Enhanced Referral group.

The biggest predictors of retinal sensitivity loss during 2 years of anti-VEGF treatment included RPE atrophy, Type 2 MNV, cystoid intraretinal spaces, and the presence of SRT.

In this segment of her interview, Dr. Arkin was asked about news, recent research, and therapies for patients with scleroderma, in honor of National Scleroderma Awareness Month.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

This interview with Dr. Arkin involved a discussion, in honor of June being National Scleroderma Awareness Month, of information on underlying causes and new research on the skin condition.

Intravitreal anti-VEGF injections were associated with an increase in the likelihood of systemic adverse events among patients with diabetic retinopathy.

New prognostic model enhances methotrexate monitoring for immune-mediated inflammatory diseases.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our May 2023 month-in-review features new FDA approvals, the future of artificial intelligence in eye care, and interesting crossover coverage.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Within the reactive care gout conversations, “pain” and “swelling” were significantly more likely to be mentioned when compared with proactive care conversations.

New data indicating this connection suggests a need for clinicians to take into account cardiovascular examination for patients with both the skin disorder and symptoms suggestive of incident venous thromboembolism.

Between 2000 and 2019, age-standardized incidence rates of autoimmune diseases increased by 4%.

Participants who only initiated non-stimulant therapy for ADHD had significantly greater odds of past-year prescription stimulant misuse than the population controls.

Adverse events were significantly more frequently reported by pregnant patients when compared with non-pregnant patients. However, no differences were observed when comparing pregnant patients with autoimmune disease and healthy controls.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

This research was conducted to identify distinct subgroups of those with atopic dermatitis, and the findings may help to promote better counseling and treatment options.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.

Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

The results of the study provide a proof of concept for upadacitinib treatment in patients with systemic lupus erythematosus.

The analysis of adults with Type 2 diabetes found 33.4% showed signs of undetected CVD, as indicated by elevated levels of 2 cardiac biomarkers, compared to only 16.1% of those without diabetes.

Those with higher psoriasis severity was associated with a higher improvement in anxiety/depression at the second timepoint.

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

Data indicate dazodalibep has the potential to address unmet therapeutic needs for patients with Sjögren’s syndrome.

These findings are relevant given that if labels are incorrectly identified, those with allergies may be at risk of severe reactions or receive suboptimal treatment.

Recent research from Japan indicates that there are several comorbidities identified for patients with psoriasis, raising awareness of incidental findings in CT analysis.